The ReDiscover study is a clinical trial for people who have advanced or metastatic cancer with a PIK3CA mutation. The clinical trial will test a new investigational drug to learn if it can target and inhibit the PI3Ka protein that is created incorrectly by a mutated PIK3CA gene.
Study participants may be able to join the study if they meet the following requirements:
- • Adult (18 years of age or older)
- • Have advanced or metastatic cancer with a documented PIK3CA mutation.
- • Qualifying cancers include breast cancer, clear cell ovarian, head and neck, cervical, and others. Your oncologist can help you confirm if you have a PIK3CA genetic mutation.
Additional eligibility criteria apply. Talk to a study doctor to learn more.
Study participants can expect the following:
- Review & sign the Informed Consent Form.
- Screening: Receive study health assessments including a physical exam, review of medical history, blood and urine tests, and heart tests, among others, to confirm if you qualify for the study.
- Treatment period: You will take the study drug for as long you are benefitting from it. Participants with breast cancer may also receive fulvestrant (an approved cancer drug) as injections. These participants may also receive palbociclib or ribociclib (both approved cancer drugs), or atirmociclib (an additional investigational drug, also known as PF-07220060). Some patients may also receive the study drug with letrozole (an approved cancer drug) and either palbociclib or atirmociclib. Palbociclib, ribociclib, atirmociclib, and letrozole are tablets or capsules taken by mouth. The study staff will tell you when to take each of the different drugs.
- Follow-up period: Receive study health assessments.
Participation in this clinical trial is voluntary. You can ask any questions you have and may leave the study at any time, for any reason.
